Hydrogen sulfide upregulates cyclooxygenase-2 and prostaglandin E metabolite in sepsis-evoked acute lung injury via transient receptor potential vanilloid type 1 channel activation

Journal of Immunology

Volumn 187, Issue 9, 2011, Pages 4778-4787

  Ang, Seah Fang ^a,b,c   Sio, Selena W S ^b   Moochhala, Shabbir M ^b,d   MacAry, Paul A ^a,b,c   Bhatia, Madhav ^e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DSO NATIONAL LABORATORIES   (Singapore)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAZEPINE; CYCLOOXYGENASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROGEN SULFIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PADGEM PROTEIN; PARECOXIB; PROSTAGLANDIN E; SODIUM DITHIONITE; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EDEMA; ENZYME ACTIVITY; ENZYME INHIBITION; LUNG EDEMA; LUNG HEMORRHAGE; LUNG INJURY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SEPSIS; TREATMENT RESPONSE; UPREGULATION;

ACUTE LUNG INJURY; ANIMALS; CECUM; CYCLOOXYGENASE 2; DINOPROSTONE; HYDROGEN SULFIDE; LIGATION; LUNG; MALE; MICE; PUNCTURES; SEPSIS; TRPV CATION CHANNELS; UP-REGULATION;

EID: 80555149806     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101559     Document Type: Article

References (56)

1. Russell, J. A., J. Boyd, T. Nakada, S. Thair, and K. R. Walley. 2011. Molecular mechanisms of sepsis. Contrib. Microbiol. 17: 48-85.
2. Varisco, B. M. 2011. The pharmacology of acute lung injury in sepsis. Adv. Pharmacol. Sci. 2011: 254619.
3. Wheeler, A. P., and G. R. Bernard. 2007. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 369: 1553-1564. (Pubitemid 46670280)
4. Zhang, H., L. Zhi, P. K. Moore, and M. Bhatia. 2006. Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L1193-L1201. (Pubitemid 43830864)
5. Szabó, C. 2007. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 6: 917-935.
6. Ang, S. F., S. M. Moochhala, and M. Bhatia. 2010. Hydrogen sulfide promotes transient receptor potential vanilloid 1-mediated neurogenic inflammation in polymicrobial sepsis. Crit. Care Med. 38: 619-628.
7. Geppetti, P., S. Materazzi, and P. Nicoletti. 2006. The transient receptor potential vanilloid 1: role in airway inflammation and disease. Eur. J. Pharmacol. 533: 207-214. (Pubitemid 43348347)
8. Ricciotti, E., and G. A. FitzGerald. 2011. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31: 986-1000.
9. Ohara, M., T. Sawa, K. Kurahashi, J. P. Wiener-Kronish, V. Doshi, I. Kudoh, and M. A. Gropper. 1998. Induction of cyclooxygenase-2 in alveolar macrophages after acid aspiration: selective cyclooxygenase-2 blockade reduces interleukin-6 production. Anesthesiology 88: 1014-1022. (Pubitemid 28193329)
10. Gust, R., J. K. Kozlowski, A. H. Stephenson, and D. P. Schuster. 1999. Role of cyclooxygenase-2 in oleic acid-induced acute lung injury. Am. J. Respir. Crit. Care Med. 160: 1165-1170. (Pubitemid 29487455)
11. Ejima, K., M. D. Layne, I. M. Carvajal, P. A. Kritek, R. M. Baron, Y. H. Chen, J. Vom Saal, B. D. Levy, S. F. Yet, and M. A. Perrella. 2003. Cyclooxygenase-2- deficient mice are resistant to endotoxin-induced inflammation and death. FASEB J. 17: 1325-1327.
12. Li, B., Y. M. Li, X. Li, B. Shi, M. Y. He, X. L. Zhu, W. C. Zhou, M. S. Wachtel, and E. Frezza. 2009. COX-2 inhibition improves immune system homeostasis and decreases liver damage in septic rats. J. Surg. Res. 157: 43-47.
13. Shoup, M., L. K. He, H. Liu, R. Shankar, and R. Gamelli. 1998. Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection. J. Trauma 45: 215-220, discussion 220-221.
14. Sio, S. W., S. F. Ang, J. Lu, S. Moochhala, and M. Bhatia. 2010. Substance P upregulates cyclooxygenase-2 and prostaglandin E metabolite by activating ERK1/2 and NF-kappaB in a mouse model of burn-induced remote acute lung injury. J. Immunol. 185: 6265-6276.
15. Koon, H. W., D. Zhao, Y. Zhan, S. H. Rhee, M. P. Moyer, and C. Pothoulakis. 2006. Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells. J. Immunol. 176: 5050-5059.
16. Gallicchio, M., E. Benetti, A. C. Rosa, and R. Fantozzi. 2009. Tachykinin receptor modulation of cyclooxygenase-2 expression in human polymorphonuclear leucocytes. Br. J. Pharmacol. 156: 486-496.
17. Gallicchio, M., A. C. Rosa, E. Benetti, M. Collino, C. Dianzani, and R. Fantozzi. 2006. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. Br. J. Pharmacol. 147: 681-689.
18. Chen, Y., P. Chen, M. Hanaoka, Y. Droma, and K. Kubo. 2008. Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology 13: 1014-1021.
19. Lappi-Blanco, E., R. Kaarteenaho-Wiik, P. K. Maasilta, S. Anttila, P. Pääkkö, and H. J. Wolff. 2006. COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am. J. Clin. Pathol. 126: 717-724. (Pubitemid 44707622)
20. Carpagnano, G. E., A. Spanevello, G. P. Palladino, C. Gramiccioni, C. Ruggieri, F. Carpagnano, and M. P. Foschino Barbaro. 2010. Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: how hot is the link? Lung Cancer 67: 108-113.
21. Hahn, E. L., H. H. Tai, L. K. He, and R. L. Gamelli. 1999. Burn injury with infection alters prostaglandin E2 synthesis and metabolism. J. Trauma 47: 1052-1057, discussion 1057-1059.
22. Futaki, N., S. Takahashi, T. Kitagawa, Y. Yamakawa, M. Tanaka, and S. Higuchi. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflamm. Res. 46: 496-502.
23. Hu, L. F., T. T. Pan, K. L. Neo, Q. C. Yong, and J. S. Bian. 2008. Cyclooxygenase- 2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardiomyocytes. Pflugers Arch. 455: 971-978.
24. Attene-Ramos, M. S., G. M. Nava, M. G. Muellner, E. D. Wagner, M. J. Plewa, and H. R. Gaskins. 2010. DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells. Environ. Mol. Mutagen. 51: 304-314.
25. Teagarden, D. L., and N. Sandeep. 2007. Case study: parecoxib: a prodrug of valdecoxib. In Prodrugs: Challenges and Rewards (Part 1, Biotechnology: Pharmaceutical Aspects). V. J. Stellar, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag, and J. W. Tilley, eds. Springer, New York, p. 1335-1346.
26. Padi, S. S., N. K. Jain, S. Singh, and S. K. Kulkarni. 2004. Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur. J. Pharmacol. 491: 69-76. (Pubitemid 38501777)
27. Talley, J. J., S. R. Bertenshaw, D. L. Brown, J. S. Carter, M. J. Graneto, M. S. Kellogg, C. M. Koboldt, J. Yuan, Y. Y. Zhang, and K. Seibert. 2000. N- [[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. 43: 1661-1663. (Pubitemid 30304998)
28. Labarca, C., and K. Paigen. 1980. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102: 344-352. (Pubitemid 10115803)
29. Zuege, D., S. Suzuki, and Y. Berthiaume. 1996. Increase of lung sodiumpotassium- ATPase activity during recovery from high-permeability pulmonary edema. Am. J. Physiol. 271: L896-L909.
30. Pittet, J. F., M. J. Griffiths, T. Geiser, N. Kaminski, S. L. Dalton, X. Huang, L. A. Brown, P. J. Gotwals, V. E. Koteliansky, M. A. Matthay, and D. Sheppard. 2001. TGF-beta is a critical mediator of acute lung injury. J. Clin. Invest. 107: 1537-1544. (Pubitemid 32574640)
31. Pittet, J. F., J. P. Wiener-Kronish, M. C. McElroy, H. G. Folkesson, and M. A. Matthay. 1994. Stimulation of lung epithelial liquid clearance by endogenous release of catecholamines in septic shock in anesthetized rats. J. Clin. Invest. 94: 663-671. (Pubitemid 24250997)
32. Piper, P. J. 1974. Release and metabolism of prostaglandins in lung tissue. Pol. J. Pharmacol. Pharm. 26: 61-72.
33. Piper, P. J., J. R. Vane, and J. H. Wyllie. 1970. Inactivation of prostaglandins by the lungs. Nature 225: 600-604.
34. Wyllie, J. H., P. J. Piper, and J. R. Vane. 1969. Fate of prostaglandins in the lungs. Br. J. Surg. 56: 623.
35. Granström, E., M. Hamberg, G. Hansson, and H. Kindahl. 1980. Chemical instability of 15-keto-13,14-dihydro-PGE2: the reason for low assay reliability. Prostaglandins 19: 933-957. (Pubitemid 10013224)
36. Bothwell, W., M. Verburg, M. Wynalda, E. G. Daniels, and F. A. Fitzpatrick. 1982. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. J. Pharmacol. Exp. Ther. 220: 229-235. (Pubitemid 12171972)
37. Maclouf, J., J. Grassi, and P. Pradelles. 1987. Development of enzymeimmunoassay techniques for the measurement of eicosanoids. In Prostaglandin and Lipid Metabolism in Radiation Injury. T. L. J. Walden, and H. N. Hughes, eds. Plenum Press, Rockville, MD, p. 355-364.
38. Ivanov, A. I., A. C. Scheck, and A. A. Romanovsky. 2003. Expression of genes controlling transport and catabolism of prostaglandin E2 in lipopolysaccharide fever. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284: R698-R706. (Pubitemid 36347792)
39. Duffield-Lillico, A. J., J. O. Boyle, X. K. Zhou, A. Ghosh, G. S. Butala, K. Subbaramaiah, R. A. Newman, J. D.Morrow,G. L.Milne, and A. J. Dannenberg. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5- lipoxygenase pathway. Cancer Prev. Res. (Phila) 2: 322-329.
40. Gross, N. D., J. O. Boyle, J. D. Morrow, M. K. Williams, C. S. Moskowitz, K. Subbaramaiah, A. J. Dannenberg, and A. J. Duffield-Lillico. 2005. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin. Cancer Res. 11: 6087-6093. (Pubitemid 41170341)
41. Mok, Y. Y., M. S. Atan, C. Yoke Ping, W. Zhong Jing, M. Bhatia, S. Moochhala, and P. K. Moore. 2004. Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. Br. J. Pharmacol. 143: 881-889. (Pubitemid 39664847)
42. Zhang, H., S. M. Moochhala, and M. Bhatia. 2008. Endogenous hydrogen sulfide regulates inflammatory response by activating the ERK pathway in polymicrobial sepsis. J. Immunol. 181: 4320-4331.
43. Cuzzocrea, S., E. Mazzon, L. Sautebin, L. Dugo, I. Serraino, A. De Sarro, and A. P. Caputi. 2002. Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. Biochem. Pharmacol. 63: 785-795. (Pubitemid 34457712)
44. Fukushima, R., J. W. Alexander, J. Z. Wu, J. X. Mao, K. Szczur, A. M. Stephens, J. D. Ogle, and C. K. Ogle. 1994. Time course of production of cytokines and prostaglandin E2 by macrophages isolated after thermal injury and bacterial translocation. Circ. Shock 42: 154-162. (Pubitemid 24142908)
45. Portanova, J. P., Y. Zhang, G. D. Anderson, S. D. Hauser, J. L. Masferrer, K. Seibert, S. A. Gregory, and P. C. Isakson. 1996. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med. 184: 883-891.
46. Rasley, A., I. Marriott, C. R. Halberstadt, K. L. Bost, and J. Anguita. 2004. Substance P augments Borrelia burgdorferi-induced prostaglandin E2 production by murine microglia. J. Immunol. 172: 5707-5713. (Pubitemid 38542075)
47. Zhang, H., A. Hegde, S. W. Ng, S. Adhikari, S. M. Moochhala, and M. Bhatia. 2007. Hydrogen sulfide up-regulates substance P in polymicrobial sepsisassociated lung injury. J. Immunol. 179: 4153-4160.
48. Scully, M., C. Gang, C. Condron, D. Bouchier-Hayes, and A. J. Cunningham. 2011. Protective role of cyclooxygenase (COX)-2 in experimental lung injury: evidence of a lipoxin A4-mediated effect. J. Surg. Res. DOI: 10.1016/j.jss. 2011.02.020.
49. Fukunaga, K., P. Kohli, C. Bonnans, L. E. Fredenburgh, and B. D. Levy. 2005. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174: 5033-5039.
50. Bonnans, C., K. Fukunaga,M. A. Levy, and B. D. Levy. 2006. Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. Am. J. Pathol. 168: 1064-1072.
51. Park, G. Y., and J. W. Christman. 2006. Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L797-L805.
52. Hata, A. N., and R. M. Breyer. 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103: 147-166. (Pubitemid 39209041)
53. Nataraj, C., D. W. Thomas, S. L. Tilley, M. T. Nguyen, R. Mannon, B. H. Koller, and T. M. Coffman. 2001. Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J. Clin. Invest. 108: 1229-1235. (Pubitemid 32995382)
54. Göggel, R., S. Hoffman, R. Nüsing, S. Narumiya, and S. Uhlig. 2002. Plateletactivating factor-induced pulmonary edema is partly mediated by prostaglandin E(2), E-prostanoid 3-receptors, and potassium channels. Am. J. Respir. Crit. Care Med. 166: 657-662. (Pubitemid 34971846)
55. Levy, B. D., C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2: 612-619. (Pubitemid 32677628)
56. McMahon, B., and C. Godson. 2004. Lipoxins: endogenous regulators of inflammation. Am. J. Physiol. Renal Physiol. 286: F189-F201. (Pubitemid 38141663)